Group 1: Earnings Performance - Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.5 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.51, but worse than a loss of $0.45 per share a year ago, indicating an earnings surprise of +1.96% [1] - The company posted revenues of $0.84 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.11%, compared to year-ago revenues of $0.78 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Shares of Orchestra BioMed Holdings, Inc. have declined approximately 37% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for the company was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Group 3: Future Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $0.74 million, while for the current fiscal year, it is -$1.96 on revenues of $2.88 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the bottom 43% of Zacks industries, which may impact the stock's performance [8]

Paysafe Limited (PSFE) came out with quarterly earnings of $0.46 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Paysafe Limited? While Paysafe Limited has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address ...

Company Performance - Liquidia Technologies, Inc. reported a quarterly loss of $0.49 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.43, and compared to a loss of $0.37 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $8.84 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 124.46%, and showing significant growth from $3.66 million in the same quarter last year [2] - Over the last four quarters, Liquidia has not surpassed consensus EPS estimates, indicating challenges in meeting earnings expectations [2] Stock Performance - Liquidia Technologies shares have increased approximately 80.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $11.67 million, and for the current fiscal year, it is -$1.60 on revenues of $42.59 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Liquidia belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting a challenging environment for stocks in this sector [8] - The performance of Liquidia's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Flowers Foods, Inc. (FLO) is expected to report revenue growth of 3.6% year-over-year, with a consensus estimate of $1.27 billion for Q2 2025 [1] - The earnings consensus has decreased by a penny to 29 cents per share, reflecting a significant decline of 19.4% compared to the previous year [2] Group 1: Company Strategy and Focus - The company is prioritizing core strategies such as team development, brand focus, margin prioritization, strategic innovations, and prudent mergers and acquisitions [3] - FLO is executing a portfolio strategy by exiting low-margin businesses and replacing them with margin-accretive opportunities while enhancing its cost structure [10] - Investments in brands, product mix, and technology are aimed at driving volume and market share gains [4][10] Group 2: Market Challenges - The upcoming fiscal second-quarter results are likely to be impacted by a challenging consumer environment characterized by shifts in spending behavior and increased costs due to heightened promotional activities [5] - Higher selling, distribution, and administrative expenses, along with workforce-related and acquisition costs, are additional challenges [5] - Persistent weakness in categories such as traditional bread, cake, and private label is expected to negatively affect performance, with a projected 2% dip in overall volumes for the quarter [6][10] Group 3: Earnings Prediction - The current model does not predict an earnings beat for FLO, with an Earnings ESP of -1.49% and a Zacks Rank of 4 (Sell) [7]

分组1 - Skechers reported quarterly earnings of $1.13 per share, exceeding the Zacks Consensus Estimate of $0.83 per share, and showing an increase from $0.91 per share a year ago, resulting in an earnings surprise of +36.14% [1] - The company achieved revenues of $2.44 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.50%, and up from $2.16 billion year-over-year [2] - Over the last four quarters, Skechers has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 6.3% since the beginning of the year, while the S&P 500 has gained 7.8% [3] - The current consensus EPS estimate for the coming quarter is $0.93 on revenues of $2.53 billion, and for the current fiscal year, it is $3.65 on revenues of $9.67 billion [7] - The Zacks Industry Rank for Shoes and Retail Apparel is currently in the bottom 30% of over 250 Zacks industries, indicating potential challenges for the sector [8]

分组1 - fuboTV Inc. reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to a loss of $0.04 per share a year ago, representing an earnings surprise of +150.00% [1] - The company posted revenues of $379.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.34%, although this is a decrease from year-ago revenues of $389.22 million [2] - fuboTV shares have increased approximately 193.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $369.02 million, with a breakeven estimate on revenues of $1.57 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Broadcast Radio and Television sector is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8]

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.67%. A quarter ago, it was expected that this company would post a loss of $0.1 per share when it actually produced a loss of $0.94, delivering a surprise of -840%.Over the last four quarters, the company has ...

分组1 - Stem, Inc. reported a quarterly loss of $3.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $3, representing an earnings surprise of -24.33% [1] - The company posted revenues of $38.37 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 15.93%, and showing an increase from $34 million in the same quarter last year [2] - Over the last four quarters, Stem has surpassed consensus EPS estimates two times and topped revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 3.4% since the beginning of the year, while the S&P 500 gained 7.9% [3] - The current consensus EPS estimate for the coming quarter is -$2.00 on revenues of $36.3 million, and for the current fiscal year, it is -$10.20 on revenues of $145.2 million [7] - The Computers - IT Services industry, to which Stem belongs, is currently in the bottom 40% of the Zacks industry rankings, indicating potential challenges ahead [8]

Group 1: Earnings Performance - Globalstar reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of a loss of $0.09 per share, and improved from a loss of $0.15 per share a year ago, representing an earnings surprise of +244.44% [1] - The company posted revenues of $67.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.15% and increasing from $60.38 million year-over-year [2] Group 2: Stock Performance and Outlook - Globalstar shares have declined approximately 15.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $68.23 million, and for the current fiscal year, it is -$0.35 on revenues of $261.71 million [7] Group 3: Industry Context - The Satellite and Communication industry, to which Globalstar belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Group 1 - Relay Therapeutics reported a quarterly loss of $0.41 per share, better than the Zacks Consensus Estimate of a loss of $0.49, and an improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of +16.33% [1] - The company achieved revenues of $0.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 35.40%, compared to zero revenues a year ago [2] - Relay Therapeutics shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Relay Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.45 on $0.5 million in revenues, and -$1.86 on $19.09 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]